Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma

Stopped Poor enrollment and ability to radioconjugate Daclizumab. Neither Center for Cancer Research (CCR) or Nuclear Medicine/Radiology wanted to do the facilities upgrade and hire personnel needed to radioconjugate the drug at the Clinical Center.

Conditions

• Hodgkin Disease
• Hodgkin Lymphoma

Interventions

• PROCEDURE: Auto stem cell transplant
• DRUG: BEAM
• RADIATION: 111In-daclizumab
• RADIATION: 90Y-daclizumab

Sponsor

National Cancer Institute (NCI)